Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151111 | 0.82 | L3MBTL1 (0.42) | ALDH1A1LMNACRBNL3MBTL1KDM4E | |
| SCHEMBL7614894 | 0.77 | PKM (0.51) | ALDH1A1LMNACRBNDDB1L3MBTL1 | |
| SCHEMBL8151927 | 0.75 | SMN1; SMN2 (0.54) | ALDH1A1CRBNDDB1DUT | |
| SCHEMBL11666542 | 0.73 | CRBN (0.52) | ALDH1A1LMNACRBNDDB1L3MBTL1 | |
| SCHEMBL2899640 | 0.73 | ALDH1A1 (0.59) | ALDH1A1LMNAL3MBTL1KDM4EMEN1 | |
| SCHEMBL2119230 | 0.72 | ALDH1A1 (0.44) | ALDH1A1LMNACRBNDDB1L3MBTL1 | |
| SCHEMBL3472507 | 0.71 | CRBN (0.47) | ALDH1A1LMNACRBNDDB1L3MBTL1 | |
| SCHEMBL8135756 | 0.70 | DUT (0.58) | ALDH1A1LMNAL3MBTL1DUT | |
| SCHEMBL25227716 | 0.70 | DDB1 (0.54) | ALDH1A1CRBNDDB1L3MBTL1MEN1 | |
| Glyoxylate SCHEMBL28498390 | 0.70 | CRBN (0.42) | ALDH1A1LMNACRBNDDB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308511-A1 | Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature. | Mermaid Pharmaceuticals GmbH (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-4281188-A2 | GENE ACTIVATION TARGETS FOR ENHANCED HUMAN T CELL FUNCTION | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11821042-B2 | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment | CORNELL UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210130903-A1 | TARGETING CHROMOSOMAL INSTABILITY AND DOWNSTREAM CYTOSOLIC DNA SIGNALING FOR CANCER TREATMENT | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2021-05-06 | — | — | US | disclosed |
| EP-2138573-A1 | Protein kinase stress-related polypeptides and methods of use in plants | BASF Plant Science GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060205924-A1 | Spliced variants of lgr6 | MUDA MARCO | 2006-09-14 | — | — | US | disclosed |
| US-20030069195-A1 | Suppression of polymorphic alleles | SPARK THERAPEUTICS, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11821042-B2 | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment | NFKB2, AURKB, NFKBIA | ALDH1A1 4722/4885LMNA 952/4885CRBN 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.